sickle cell

People with sickle cell disease (SCD) are at an increased risk of venous thromboembolism (VTE). Women, in particular, with SCD may be at a higher risk of blood clots than their male counterparts due to other risk factors, such as contraceptives or hormone therapies containing estrogen. People with sickle cell disease (SCD) face the possibility...

Patients with sickle cell disease (SCD) often face inadequate care, which can lead to unnecessary hospital visits and preventable complications. Barriers to care for patients with SCD span individual, interpersonal, provider, and socio-environmental levels. Sickle cell disease (SCD) is a severe, inherited disorder that disproportionately affects African Americans in the United States. Despite available treatments,...

Economic disparities are higher across patients with SCD compared to the population without SCD, and these disparities may worsen existing racial disparities. One analysis simulated the effect of a cure on the financial well-being of patients with SCD. Economic disparities exist across patients with sickle cell disease (SCD), especially those of different racial and socioeconomic...

Palliative care can help decrease symptoms and improve the quality of care of patients with sickle cell disease, especially those who are hospitalized. However, the use of palliative care can vary across different populations of hospitalized patients with sickle cell disease. Sickle cell disease (SCD) is a serious, inherited blood disorder characterized by chronic complications,...

On Monday November 25 the U.S. Food and Drug Administration granted accelerated approval to Oxbryta (voxelotor) for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older. “Today’s approval provides additional hope to the 100,000 people in the U.S., and the more than 20 million globally, who...

I have lived with sickle cell disease for 48 years. The toll it takes goes far beyond pain – it has impacted me emotionally, economically, and psychosocially. I missed childhood activities because I was too sick or tired. I missed school days and worked harder to catch up on missed assignments. I learned to live...

On November 15 the U.S. Food and Drug Administration approved Adakveo (crizanlizumab-tmca), a treatment to reduce the frequency of vaso-occlusive crisis – a common and painful complication of sickle cell disease that occurs when blood circulation is obstructed by sickled red blood cells – for patients age 16 years and older. “Hope has never been...